The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...

ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Welcome to the SIGA Business Update Call. Before we turn the call ...

But when the pain got too much the man decided to go to the infectious diseases clinic at the Alfred to get the Tecovirimat TPOXX antiviral treatment. However when he presented to the emergency ...

It began as a single painful spot on his nose. But what appeared to be an innocent blemish quickly turned into a searing ...

This article covers precautions such as vaccination and isolation, available therapies like tecovirimat, and guidelines on fetal monitoring. Conclusion: Finally, this paper proposes an integrated ...